These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
676 related articles for article (PubMed ID: 29738953)
41. A novel class of anthraquinone-based HDAC6 inhibitors. Song Y; Lim J; Seo YH Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327 [TBL] [Abstract][Full Text] [Related]
42. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif. Yang J; Cheng G; Xu Q; Luan S; Wang S; Liu D; Zhao L Bioorg Med Chem; 2018 May; 26(8):1418-1425. PubMed ID: 29500130 [TBL] [Abstract][Full Text] [Related]
43. Beyond the Selective Inhibition of Histone Deacetylase 6. Rodrigues DA; Thota S; Fraga CA Mini Rev Med Chem; 2016; 16(14):1175-84. PubMed ID: 27121714 [TBL] [Abstract][Full Text] [Related]
44. Re-exploration of tetrahydro-β-carboline scaffold: Discovery of selective histone deacetylase 6 inhibitors with neurite outgrowth-promoting and neuroprotective activities. Wen W; Hu J; Wang C; Yang R; Zhang Y; Huang B; Qiao T; Wang J; Chen X Bioorg Med Chem Lett; 2024 Apr; 102():129670. PubMed ID: 38387692 [TBL] [Abstract][Full Text] [Related]
45. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors. De Vreese R; D'hooghe M Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994 [TBL] [Abstract][Full Text] [Related]
46. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity. Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969 [TBL] [Abstract][Full Text] [Related]
47. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity. Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303 [TBL] [Abstract][Full Text] [Related]
48. Design, synthesis and biological activity of oxyevodiamine-based histone deacetylase 6 inhibitors. Li SY; Guo JS; Yang YJ J Asian Nat Prod Res; 2024 Nov; 26(11):1328-1338. PubMed ID: 38945152 [TBL] [Abstract][Full Text] [Related]
49. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity. Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672 [TBL] [Abstract][Full Text] [Related]
51. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor. Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059 [TBL] [Abstract][Full Text] [Related]
52. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity. Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281 [TBL] [Abstract][Full Text] [Related]
53. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma. Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690 [TBL] [Abstract][Full Text] [Related]
54. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs. Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307 [TBL] [Abstract][Full Text] [Related]
55. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors. Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121 [TBL] [Abstract][Full Text] [Related]
56. Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells. Kumar D; Sarma P; Bhadra MP; Tangutur AD Anticancer Agents Med Chem; 2019; 19(6):750-759. PubMed ID: 30621566 [TBL] [Abstract][Full Text] [Related]
57. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation. Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601 [TBL] [Abstract][Full Text] [Related]
58. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors. Tavares MT; Kozikowski AP; Shen S Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922 [TBL] [Abstract][Full Text] [Related]
59. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019). He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106 [TBL] [Abstract][Full Text] [Related]
60. Metal-Free Direct Amidation of Naphthoquinones Using Hydroxamic Acids as an Amide Source: Application in the Synthesis of an HDAC6 Inhibitor. Zhang C; Chou CJ Org Lett; 2016 Nov; 18(21):5512-5515. PubMed ID: 27759399 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]